NCT04227054Active, not recruitingNot Applicable
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - A Prospective Single Center Safety Study
Shape Memory Medical, Inc.4 sites in 1 country15 target enrollmentStarted: September 9, 2020Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Shape Memory Medical, Inc.
- Enrollment
- 15
- Locations
- 4
- Primary Endpoint
- Incidence of related major adverse events (MAEs)
Study Overview
Brief Summary
To determine the safety and efficacy of IMPEDE-FX Embolization Plug and/or IMPEDE-FX Rapid Fill to fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •≥18 years of age
- •A candidate for elective EVAR of an infrarenal aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women
Exclusion Criteria
- •An inability to provide informed consent
- •Enrolled in another clinical study
- •Concomitant iliac artery ectasia or aneurysm (common iliac artery diameter >24 mm)
- •Patent AAA sac feeding vessels (within the sac) >4 mm in diameter
- •Volume of AAA sac to be filled after stent graft placement <30 mL or >135 mL, based on pre-procedure CTA (i.e. aortic flow volume exclusive of stent graft volume)
- •Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II Stent Graft, or Endologix Ovation Alto Abdominal Stent Graft System to treat the AAA
- •Planned use of the chosen stent graft outside its instructions for use (IFU)
- •Planned use of fenestrated or chimney stent grafts
- •Study participants in which stent graft placement is abandoned for any reason, and/or in which the investigator decides, during the course of the stent graft placement, that the study procedure may not be appropriate
- •Planned use of embolic devices other than the investigational product to embolize the AAA sac
- •Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac
- •Ruptured, leaking, or mycotic (infected) aneurysm
- •Aneurysmal disease of the descending thoracic aorta
- •Coagulopathy or uncontrolled bleeding disorder
- •Long-term (>6 months prior to the procedure) use of direct oral anticoagulant or any vitamin K antagonist anticoagulant use
- •Serum creatinine level >2.5 mg/dL;
- •Cerebrovascular accident within 3 months prior to the procedure
- •Myocardial infarction and/or major heart surgery within 3 months prior to the procedure
- •Atrial fibrillation that is not well rate controlled
- •Unable or unwilling to comply with study follow-up requirements
- •Life expectancy of <2 years post-procedure
- •Known hypersensitivity or contraindication to platinum, iridium, or polyurethane
- •A condition that inhibits radiographic visualization during the implantation procedure
- •History of allergy to contrast medium that cannot be managed medically
- •Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the study
- •Pregnant or a lactating female. For females of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study
- •Prisoner or member of other vulnerable population.
Arms & Interventions
Intervention
Experimental
Intervention: IMPEDE-FX Embolization Plug (Device)
Outcomes
Primary Outcomes
Incidence of related major adverse events (MAEs)
Time Frame: 30 days post-procedure
Incidence of related major adverse events (MAEs)
Efficacy - Technical Success
Time Frame: Immediately after the intervention
Technical success, defined as filling of the residual flow lumen of the AAA sac with investigational products
Secondary Outcomes
- Incidence of related major adverse events (MAEs)(5 years post-procedure)
- Incidence of related serious adverse events (SAEs)(5 years post-procedure)
- Efficacy - Type II endoleaks(5 years post-procedure)
- Efficacy - Type I and type III endoleaks(5 years post-procedure)
- Efficacy - AAA sac diameter/volume(5 years post-procedure)
- Efficacy - Open repair(5 years post-procedure)
- Efficacy - Reinterventions(5 years post-procedure)
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - NetherlandsAbdominal Aortic AneurysmNCT04751578Shape Memory Medical, Inc.15
Active, not recruiting
Not Applicable
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of ExpansionAortic Aneurysm, AbdominalNCT06029660Shape Memory Medical, Inc.180
Not yet recruiting
Not Applicable
Pre-emptive Abdominal Aortic Aneurysm Sac Embolization During EVARAbdominal Aortic Aneurysm Without RuptureNCT05575570Rigshospitalet, Denmark124
Completed
Not Applicable
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - A Prospective Multicenter Study.abdominal aortic widening1000318410002363abdominal aortic aneurysmNL-OMON54411Shape Memory Medical15
Active, not recruiting
Not Applicable
EndoVascular Aortic Repair With Sac Embolization for the Prevention of Type II Endoleaks (the EVAR-SE Study)Abdominal Aortic AneurysmEndoleakNCT05665101Univ.-Prof. Dr. Dr. med. Daniela Branzan101